Clinical trials: Leishmaniasis
Cutaneous Leishmaniasis
WR 279,396 for the Treatment of Cutaneous Leishmaniasis
The objectives of the study are to evaluate the safety and efficacy of open label treatment with WR 279,396 (topical paromomycin \& gentamicin) in patients with non-complicated, non-severe cutaneous leishmaniasis (CL).
- Trial name
- PAGELEC (NCT01988909)
- Testing
- WR 279,396
- Where
- 2 sites in France
- Volunteers
- 18 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Leishmania Infantum Disease, Leishmaniasis, Visceral
LEISH-PED: Study on Leishmaniasis in Children
Leishmaniasis is an infection caused by Leishmania parasites. In children, it can affect the skin or internal organs. Diagnosis may be delayed because the signs and symptoms can be similar to those of other conditions.
- Conditions
- Leishmania Infantum Disease, Leishmaniasis, Visceral, Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous
- Trial name
- LEISH-PED (NCT07504757)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Meyer Children's Hospital IRCCS
Leishmaniasis
Sodium Stibogluconate Treatment of Leishmaniasis
Leishmanias is a disease caused by the bite of sandflies and is found in many parts of the world including the Europe, Southwest Asia, Africa and the Middle East.
- Trial name
- NCT00662012
- Testing
- Sodium Stibogluconate (SSG)
- Where
- United States
- Volunteers
- 414 people
- Sponsor
- U.S. Army Medical Research and Development Command
Visceral Leishmaniasis
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
Symptomatic Visceral Leishmaniasis(VL)is fatal; Due to the increasing resistance to standard therapy with antimonials, there is a need for new safe, efficacious, low-cost therapies for the treatment of VL.
- Trial name
- NCT00216346
- Testing
- Paromomycin sulfate, Amphotericin B
- Where
- 4 sites in India
- Volunteers
- 667 people
- Sponsor
- PATH
Treatment of Cutaneous Leishmaniasis in Brazil.
Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)
The hypothesis of this trial is that the therapeutic activity and safety of oral miltefosine in Brazilian patients with cutaneous leishmaniasis is similar or superior to the intravenous standard treatment (meglumine antimoniate …
- Trial name
- NCT00600548
- Testing
- Miltefosine., Meglumine antimoniate.
- Where
- 2 sites in Brazil
- Volunteers
- 180 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Visceral Leishmaniasis
Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil
This study is aimed to compare the efficacy and safety of medications currently used in Brazil for treatment of visceral leishmaniasis.
- Trial name
- LVBrasil (NCT01310738)
- Testing
- Antimoniate of N-methylglucamine, amphotericin B deoxycholate, Liposomal amphotericin B
- Where
- 5 sites in Brazil
- Volunteers
- 378 people
- Sponsor
- University of Brasilia
Cutaneous Leishmaniases
Spatial Analysis of Host-parasite Interactions in Cutaneous Leishmaniasis in Ethiopia
Cutaneous leishmaniasis manifestations range from self-healing localized skin ulcers/nodules to diffusely spread chronic lesions.
- Trial name
- SpatialCL (NCT05332093)
- Testing
- skin biopsy, venous blood sample (plasma, PBMC, WB), venous blood sample (HLA)
- Where
- Ethiopia
- Volunteers
- 92 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Cutaneous Leishmaniasis
Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis
This study will test whether addition of imiquimod to standard antimony therapy provides a significant benefit in subjects with newly diagnosed cutaneous leishmaniasis.
- Trial name
- NCT00257530
- Testing
- Imiquimod
- Where
- 2 sites in Peru
- Volunteers
- 80 people
- Sponsor
- Drugs for Neglected Diseases
Cutaneous Leishmaniasis
Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)
Anthroponotic Cutaneous Leishmaniasis (ACL) is a parasitic disease caused by Leishmania tropica, pentavalent antimonials (sodium stibogluconate and meglumine antimoniate) have been used as a standard treatment for leishmaniasis…
- Trial name
- NCT04340128
- Testing
- Meglumine antimoniate
- Where
- Iran
- Sponsor
- Tehran University of Medical Sciences
Cutaneous Leishmaniasis
Pharmacokinetics of Miltefosine in Children and Adults
The purpose of this study is to determine the pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis in plasma and intracellularly, and its relation with the parasitologic response.
- Trial name
- PK (NCT01462500)
- Testing
- Miltefosine
- Where
- Colombia
- Volunteers
- 60 people
- Sponsor
- Centro Internacional de Entrenamiento e Investigaciones Médicas
Visceral Leishmaniasis
A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
ImmStat@Cure is a multicentre observational study designed to assess the immune status of patients before and after treatment for visceral leishmaniasis. Forty patients and 30 controls will be recruited per site.
- Trial name
- NCT04342715
- Testing
- Sodium stibogluconate / paramomycin
- Where
- Kenya
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of York
Skin and Connective Tissue Diseases, Neglected Tropical Diseases
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited.
- Conditions
- Skin and Connective Tissue Diseases, Neglected Tropical Diseases, Leprosy, Buruli Ulcer
- Trial name
- SkincAIr (NCT07506967)
- Testing
- A mobile app with AI functionality for diagnosing skin-related NTDs
- Where
- 5 sites in Democratic Republic of the Congo, Ethiopia and 3 more
- Volunteers
- 2,420 people
- Sponsor
- Kenya Medical Research Institute
Visceral Leishmaniasis
Clinical Prognostic Score to Predict Relapse in VL
This prospective cohort study has the aim to develop a prognostic tool to predict relapse in patients suffering from visceral leishmaniasis (VL) from VL endemic regions in Ethiopia.
- Trial name
- CPS (NCT05602610)
- Testing
- No intervention
- Where
- Ethiopia
- Volunteers
- 741 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Cutaneous Leishmaniases
Evaluation of Point-of-care Tests for the Diagnosis of Cutaneous Leishmaniasis in Afghanistan
New point-of-care (POC) tests are needed and assessing the performance of these tests for cutaneous leishmaniasis (CL) in Afghanistan may help increasing the number of CL patients with access to accurate diagnosis, and enable…
- Trial name
- CLeishPOCAFG (NCT03435419)
- Testing
- LoopampTM Leishmania Detection Kit, CL DetectTM Rapid Test
- Volunteers
- 274 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Visceral Leishmaniasis
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
The purpose of this study is to assess the efficacy and safety of SSG 30 days alone, PM 21 days alone and SSG and PM as a combination course of 17 days in the treatment of patients with VL.
- Trial name
- NCT00255567
- Testing
- Sodium Stibogluconate, Paromomycin sulphate, SSG and Paromomycin sulphate
- Where
- 5 sites in Ethiopia, Kenya and 2 more
- Volunteers
- 1,142 people
- Sponsor
- Drugs for Neglected Diseases
Mucosal Leishmaniasis
Treatment of Mucosal Bolivian Leishmaniasis
The purpose of this protocol is to conduct a randomized comparison of the efficacy and tolerance of miltefosine, LAMB, and pentavalent antimony for the treatment of mucosal leishmaniasis.
- Trial name
- NCT04799236
- Testing
- Group 1: Miltefosine, Group 2: Pentavalent Antimony, Group 3: Liposomal amphotericin B
- Where
- Bolivia
- Volunteers
- 120 people
- Sponsor
- Fundacion Nacional de Dermatologia
Cutaneous Leishmaniasis
Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
Cutaneous leishmaniasis is typically treated with the parenteral product pentavalent antimony. Miltefosine is an oral agent shown to be active for mucosal leishmaniasis due to L braziliensis in Bolivia and cutaneous leishmaniasis…
- Trial name
- NCT00233545
- Testing
- miltefosine, antimony
- Where
- Bolivia
- Volunteers
- 80 people
- Sponsor
- AB Foundation
Leishmaniasis, Visceral
Visceral Leishmaniasis in Emilia-Romagna (Leishmania-2019)
According to reports in the literature, from 2012 to date, there has been an increase in the number of diagnosed cases of autochthonous visceral Leishmania in the Province of Bologna.
- Trial name
- NCT06793111
- Where
- 5 sites in Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Visceral Leishmaniasis
Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children
The purpose of this study is to determine if amphotericin B is effective against visceral leishmaniasis in Brazilian children. Amphotericin B will be compared to meglumine antimoniate which is the current approved drug used for…
- Trial name
- LVTO (NCT01032187)
- Testing
- Meglumine antimoniate, Amphotericin B-deoxycholate
- Where
- 2 sites in Brazil
- Volunteers
- 101 people
- Sponsor
- University of Brasilia
Cutaneous Leishmaniases
Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World
This study evaluates if the combination of thermotherapy (one application, 50⁰C for 30") and 3 weeks of miltefosine is safe and have a comparable cure rate with the current recommended first line treatments comprising meglumine…
- Trial name
- NCT04515186
- Testing
- Meglumine Antimoniate, Miltefosine, Thermotherapy machine
- Where
- 6 sites in Bolivia, Brazil and 2 more
- Volunteers
- 184 people
- Sponsor
- Drugs for Neglected Diseases